Vertex Pharmaceuticals Q2 2023 Earnings Preview
mohd izzuan

Vertex Pharmaceuticals (NASDAQ:VRTX) is scheduled to announce Q2 earnings results on Tuesday, August 1st, after market close.
The consensus EPS Estimate is $3.88 (+7.8% Y/Y) and the consensus Revenue Estimate is $2.42B (+10.0% Y/Y).
Over the last 2 years, VRTX has beaten EPS estimates 88% of the time and has beaten revenue estimates 88% of the time.

Over the last 3 months, EPS estimates have seen 15 upward revisions and 3 downward. Revenue estimates have seen 13 upward revisions and 2 downward.
Sell-side analysts are optimistic about the stock, giving it a consensus Buy rating, while Seeking Alpha's Quant Rating system, which is more circumspect, assigns the company a Hold rating due to valuation concerns.

More on Vertex Pharmaceuticals

Vertex And CRISPR Therapeutics - Partners On Exa-cel - But Unequally Valued
Vertex: Promising Prospects Amid Stretched Valuation
Vertex: Resilient Growth And Promising Pipeline